Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Ä«Å×°í¸®
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö (1468)
°Ô³ð â¾à (202)
¸ÂÃãÇüÀÇ·á (54)
¹ÙÀÌ¿À¸¶Ä¿ (154)
¹ÙÀÌ¿À¸ÅÆ®¸®¾ó (55)
¹ÙÀÌ¿ÀÀåºñ (323)
ºÐÀÚÇ¥ÀûÄ¡·á(MTT) (53)
À¯ÀüÀÚ Ä¡·á/RNAi (100)
Àç»ýÀÇÇÐ (125)
Ç×ü/¸é¿ª (187)
Áö¿ªº°°Ë»ö
ÃâÆÇ»ç¿¡¼­ ã±â

ºÐÀÚÇ¥ÀûÄ¡·á(MTT) ½ÃÀåÁ¶»çº¸°í¼­

ºÐÀÚÇ¥ÀûÄ¡·á(MTT) ½ÃÀåÀ» Á¶»ç ºÐ¼®ÇÑ ÀÚ·á·Î ½ÃÀå ±Ô¸ð, »ê¾÷ ºÐ¼®, ÇâÈÄ ½ÃÀå ¿¹Ãø µîÀÇ ³»¿ëÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù.
º¸°í¼­¿¡ µû¶ó¼­ ÁÖ¿ä ±â¾÷ ºÐ¼®, °æÀïȯ°æ ºÐ¼®, ¿¬±¸°³¹ß ÇöȲ, ¿µ¾÷ Àü·«, ±â¾÷ Á¦ÈÞ ÇöȲÀ» Æ÷ÇÔÇÏ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù.

»ó¼¼ºÐ·ù
Á¦¸ñ°Ë»ö
1 - 25 ¸®ºä (Àüü£º 51 °Ç) Á¤·Ä Ç¥½Ã °Ç¼ö
Small-Molecule Targeted Cancer Therapies: World Market 2011-2021
»ùÇÃ
»óǰÄÚµå :226942
¼¼°èÀÇ ¾Ï ¼ÒºÐÀÚ Ç¥ÀûÄ¡·á(Small-Molecule Targeted Cancer Therapies) ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, 2021³â±îÁöÀÇ ¼öÀͼº ¿¹Ãø, µ¿Çâ ¹× ¹ßÀü ±âȸ, ÇöÀç ¾Ï Ä¡·áÀÇ Á¦1¼±¿¡ À§Ä¡ÇÑ Á¦Ç°, Á¦¾à¾÷ü, ¼±Áø±¹°¡ ½ÃÀå¿¡ ´ëÇÑ ±¸Ã¼Àû ºÐ¼®, Á¦¾à »ê¾÷ÀÇ º¯È­°¡ ¼ÒºÐÀÚ Ç¥ÀûÄ¡·á¹ý¿¡ ¹ÌÄ¡´Â ¿µÇâ, ½ÃÀå Àü°³ µî¿¡ ´ëÇÑ ÃֽŠÁ¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,642
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Visiongain
ÆäÀÌÁö¼ö 170 Pages
Kinase-Targeted Therapeutics: Development Pipelines, Challenges, and Opportunities
»ùÇÃ
»óǰÄÚµå :210216
Ű³ª¾ÆÁ¦(Kinase)¸¦ Ç¥ÀûÀ¸·Î ÇÑ Ä¡·áÁ¦ °³¹ß µ¿Çâ, È­ÇÕ¹° °³¹ß¿¡ ÀÀ¿ëµÇ´Â ÇöÀç ±â¼ú ¹× ½ÅÈï ±â¼ú, Ű³ª¾ÆÁ¦ Á¶Àý¿¡ ´ëÇØ ¿¬±¸ÁßÀÎ ÁÖ¿ä ±â¾÷°ú ±× ÇÁ·ÎÁ§Æ®, ´Ù¾çÇÑ Å°³ª¾ÆÁ¦ Ŭ·¡½ºÀÇ Æ¯Â¡, ¾÷°è°¡ Á÷¸éÇÑ °úÁ¦, ÇöÀç µ¿Ç⠵ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2011³â 08¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö  
Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development
»ùÇÃ
»óǰÄÚµå :204890
´Ù¾çÇÑ Áúȯ¿¡ ´ëÇÑ Èıâ´Ü°è ÆÄÀÌÇÁ¶óÀÎ ºÐÀÚ(Late Stage Pipeline Molecules)ÀÇ ºñ±³ ºÐ¼®À» ½Ç½ÃÇϰí, ½ÃÀå ±âȸ¿Í ¹ÌÃæÁ· ¿ä±¸, Àü·«Àû Æò°¡, ÀÓ»ó½ÃÇèÁßÀÎ À¯¸Á ¾àÁ¦ µ¿Çâ µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GBI Research
ÆäÀÌÁö¼ö Pages: 132
Competitor Analysis: PI3K-AKT-mTOR Inhibitors
»ùÇÃ
»óǰÄÚµå :203065
¾Ï ¹× ¿©Å¸ ÀûÀÀ¿¡¼­ÀÇ PI3K-AKT-mTOR ÀúÇØÁ¦ ¿¬±¸°³¹ß ÇÁ·ÎÁ§Æ®¿Í ±â¾÷º° ¿¬±¸°³¹ß ÆÄÀÌÇÁ¶óÀÎÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 711
¹ßÇàÀÏ 2011³â 06¿ù
¸®¼­Ä¡»ç La Merie Publishing
ÆäÀÌÁö¼ö 100 Pages
Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology
»ùÇÃ
»óǰÄÚµå :200289
´Ü¹éÁúŰ³ª¾ÆÁ¦¸¦ Ȱ¿ëÇÑ ½Å¾à °³¹ß ¹× ±â¼ú Çõ½ÅÀÇ Ãֽе¿ÇâÀ» Á¶»çÇßÀ¸¸ç, ±â´ëµÇ´Â Àû¿ë ºÐ¾ß(Á¾¾ç µî), ÁÖ¿ä ÀǾàǰ °³¹ß ±â¾÷ 10»çÀÇ ÀÓ»ó½ÃÇè ÆÄÀÌÇÁ¶óÀÎ »óȲ(PhaseI¡­III), ƯÇã Ãëµæ ÇöȲ, ÇâÈÄ ±â¼ú°³¹ß Àü·« µî¿¡ ´ëÇØ ºÐ¼® ¹× °íÂûÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 05¿ù
¸®¼­Ä¡»ç GBI Research
ÆäÀÌÁö¼ö Pages: 119
Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market
»ùÇÃ
»óǰÄÚµå :170805
¼¼°èÀÇ Ç¥Àû ¿ä¹ý ½ÃÀåÀ» ºÐ¼®Çϰí, Ç¥Àû ¿ä¹ýÀÇ ÁÖ¿ä µ¿Çâ, °úÁ¦, À¯·´°ú ¹Ì±¹ÀÇ ¹ý±ÔÁ¦ ȯ°æ, ½ÃÀå ÁøÃâ ±â¾÷ÀÇ °æÀï °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 02¿ù
¸®¼­Ä¡»ç GBI Research
ÆäÀÌÁö¼ö Pages: 100
»ùÇÃ
»óǰÄÚµå :177391
¼¼°èÀÇ G ´Ü¹éÁú ¿¬°á ¼ö¿ëü (GPCR) ½ÃÀå¿¡ ÁÖ¸ñÇÏ°í ±× ±Ô¸ð¸¦ ÆÇ¸Å ±Ý¾× Ãø¸é¿¡¼­ Á¾ÇÕÀûÀÎ °üÁ¡¿¡¼­ ºÐ¼®Çϰí, 2007³âºÎÅÍ 2015³â ±îÁöÀÇ °ÉÄ£ µ¶ÀÚÀûÀÎ ÆÇ¸Å ½ÇÀû °ËÁõ ¹× ¿¹Ãø,ÀÌ ºÐ¾ß¿¡¼­ Ȱ¾àÇÏ´Â ±â¾÷ 43°÷¿¡ ´ëÇÑ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 4,500
¹ßÇàÀÏ 2011³â 02¿ù
¸®¼­Ä¡»ç Global Industry Analysts, Inc.
ÆäÀÌÁö¼ö Pages: 299
Cancer Targeted Therapies and Immunotherapies Market Forecast
»ùÇÃ
»óǰÄÚµå :129274
2009³âºÎÅÍ 2019³â±îÁöÀÇ ¼¼°è 7´ë ½ÃÀå ¾Ï Ç¥Àû¿ä¹ý(Targeted Therapies) ¹× ¸é¿ª¿ä¹ý(Cancer Targeted Therapies)ÀÇ °¢°¢ÀÇ ½ÇÀû ¹× ¿¹Ãø, ÇöÀç Ãâ½ÃµÇ¾î ÀÖ´Â ¾àÁ¦ ¹× ÆÄÀÌÇÁ¶óÀÎ ¾àÁ¦°¡ Á÷¸éÇÑ ±âȸ¿Í À§Çù, ÇâÈÄ 10³â°£ÀÇ ÁÖ¿ä ºê·£µå µ¿Çâ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 15,200
¹ßÇàÀÏ 2010³â 08¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö  
Competitor Analysis: Tau and Amyloid Beta Targeted Therapy of Alzheimer's Disease
»ùÇÃ
»óǰÄÚµå :127639
¾ËÃ÷ÇÏÀ̸Ӻ´(Alzheimer''s Disease)ÀÇ Å¸¿ì(Tau) ¹× ¾Æ¹Ð·ÎÀÌµå º£Å¸(Amyloid Beta)¸¦ Ç¥ÀûÀ¸·Î ÇÑ Ä¡·á ¹é½Å, Ç×ü, ÀúºÐÀÚ ºÐ¾ß¸¦ ºÐ¼®Çϰí, ±â¾÷ÀÇ ¿¬±¸°³¹ß µ¿ÇâÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 890
¹ßÇàÀÏ 2010³â 08¿ù
¸®¼­Ä¡»ç La Merie Publishing
ÆäÀÌÁö¼ö 105 Pages
Stakeholder Opinions: Ovarian Cancer - Approaching the era of molecular targeted therapy
»ùÇÃ
»óǰÄÚµå :125994
³­¼Ò¾ÏÀÇ °³¿ä¿Í ¹ÌÃæÁ· ¿ä±¸, ÇöÀç Ä¡·á¹ý°ú ´Ù¾çÇÑ ÀÇ·Ð, ÈÄ±â ÆÄÀÌÇÁ¶óÀÎ(Pipeline) °³¿ä, ÀÌÇØ ´ç»çÀÚ(Stakeholder)ÀÇ °ßÇØ µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,800
¹ßÇàÀÏ 2010³â 07¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 93
Threats to Avastin
»ùÇÃ
»óǰÄÚµå :118647
AvastinÀÇ °³¿ä ¹× ½ÃÀåÀÇ ±âŸ Á¦Ç°, ±â¾÷ ¹× °æÀﵿÇâ, ÇâÈÄ µ¿Çâ¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,265
¹ßÇàÀÏ 2010³â 04¿ù
¸®¼­Ä¡»ç Espicom Business Intelligence
ÆäÀÌÁö¼ö 145 pages
The Future of GPCRs in Drug Discovery: Novel technologies, leading companies, and opportunities for target expansion
»ùÇÃ
»óǰÄÚµå :121619
GPCR(G protein-coupled receptor,G´Ü¹éÁú ¿¬°á ¼ö¿ëü) ÀÇ °³¿ä¿Í â¾à±â¼ú·ÎÀÇ ÀÀ¿ë µ¿Çâ, ÀÌ ºÐ¾ßÀÇ Àü¹® ±â¾÷ °³¿ä¿Í ÇâÈÄ ½ÃÀå Àü¸Á µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,835
¹ßÇàÀÏ 2010³â 04¿ù
¸®¼­Ä¡»ç Business Insights
ÆäÀÌÁö¼ö Pages: 130
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
»ùÇÃ
¿­¶÷ ¼­ºñ½º Á¦°ø
»óǰÄÚµå :116974
¼¼°è »ýüºÐÀÚ ½Ã¾à½ÃÀå¿¡ ´ëÇØ ºÐ¼®Çϰí, »ý¹° ÀǾàǰ ¾ç»ó(modality)ÀÇ ÀåÁ¡°ú ´ÜÁ¡, Áúȯº° ¾ÛŸ¸Ó(Aptamers) Ä¡·á½ÃÀåÀÇ °³¿ä, ¹Ì±¹ ¹× ±âŸ ±¹°¡ÀÇ Æ¯Çã, ÁöÀû Àç»ê±Ç µ¿Çâ¿¡ ´ëÇÏ¿© ¾Æ·¡¿Í °°Àº ±¸¼ºÀ¸·Î ÀüÇØ µå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 4,850
¹ßÇàÀÏ 2010³â 03¿ù
¸®¼­Ä¡»ç BCC Research
ÆäÀÌÁö¼ö 153 pages
Biological Therapies for Cancer: Technologies and Global Markets
»ùÇÃ
¿­¶÷ ¼­ºñ½º Á¦°ø
»óǰÄÚµå :117617
¼¼°èÀÇ Ä¡Çè Áß, ¹ß¸Å ¿Ï·á ¹× Èı⠰³¹ß ´Ü°è¿¡ ÀÖ´Â ¾ÏÄ¡·áÁ¦¿¡ ´ëÇØ ºÐ¼®Çϰí, ½ÃÀå µ¿Çâ°ú 2014³â±îÁö 5³â ¿¹Ãø, ½ÃÀå ÁøÃâ ±â¾÷ °³¿ä¿Í ƯÇ㠺м® °á°ú¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 4,850
¹ßÇàÀÏ 2010³â 03¿ù
¸®¼­Ä¡»ç BCC Research
ÆäÀÌÁö¼ö 321 pages
Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?
»ùÇÃ
»óǰÄÚµå :117227
441°³ Ç×ü(antibody) ÀǾàǰÀÇ °³¹ß Àü·«À» ºÐ¼®Çϰí, Ãâ½Ã ¿Ï·á Á¦Ç° °³¿ä, 234°³ÀÇ ¾àÁ¦ Ç¥Àû ÇÁ·ÎÆÄÀÏ(drug target profiles) µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,553
¹ßÇàÀÏ 2010³â 03¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 1289 Pages
Kinase Therapeutics: Pipeline Assessment and Commercial Prospects
»ùÇÃ
»óǰÄÚµå :111962
Ű³ª¾ÆÁ¦¸¦ Ç¥ÀûÀ¸·ÎÇÑ ¿¬±¸ °³¹ß µ¿Çâ, ÇöÀçÀÇ Å°³ª¾ÆÁ¦ ÀúÇØÁ¦ ÆÄÀÌÇÁ¶óÀÎ, ÇöÀç±îÁöÀÇ »ó¾÷Àû ¼º°ú, ´Ü±âÀû, Àå±âÀû ½ÃÀå Àü¸Á ¹× Âü°¡ÇÏ´Â ±â¾÷ÀÇ È°µ¿À» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2010³â 01¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö 302 pages
Apoptotic Therapeutics in Oncology - Where to Commercialize?
»ùÇÃ
»óǰÄÚµå :106596
171°³ ¾ÆÆ÷Åä½Ã½º(Apotosis) ¾àÁ¦ÀÇ °³¹ß Àü·«¿¡ ´ëÇØ ºÐ¼®Çϰí, Á¦¾àȸ»çÀÇ Æ÷Æ®Æú¸®¿À °èȹ°ú ½ÅÁ¦Ç° °³¹ß °èȹÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,553
¹ßÇàÀÏ 2009³â 11¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 803 pages
Kinase Inhibitors: Global Markets
»ùÇÃ
¿­¶÷ ¼­ºñ½º Á¦°ø
»óǰÄÚµå :104223
¼¼°è Ű³ª¾ÆÁ¦ ÀúÇØÁ¦ ½ÃÀåÀÇ ÇöȲ°ú Àü¸Á¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, Á¦Ç° À¯Çü¡¤Àû¿ë Áúº´ ±¸ºÐº° ½ÃÀå ±Ô¸ð ½ÇÀû¡¤¿¹Ãø(¡­2014³â), ½ÃÆÇ Á¦Ç°°ú °³¹ßÁßÀÎ Á¦Ç°ÀÇ °³¿ä, ÁÖ¿ä ±â¾÷°ú ½ÃÀå Á¡À¯À², ±¹Á¦Àû Àü¸Á, ÇâÈÄÀÇ ¹æÇ⼺ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 4,850
¹ßÇàÀÏ 2009³â 11¿ù
¸®¼­Ä¡»ç BCC Research
ÆäÀÌÁö¼ö 184 pages
»ùÇÃ
»óǰÄÚµå :103038
»çÀÌŬ¸° ÀÇÁ¸¼º Ű³ª¾ÆÁ¦(CDK) ¾ïÁ¦Á¦¿¡ °üÇÑ Æ¯Çã µ¿ÇâÀ» »ó¼¼ÇÏ°Ô ºÐ¼®Çϰí, Ãâ¿ø µ¿Çâ ¹× ÅõÀÚ°¡ µ¿Çâ, ÇâÈÄÀÇ Àü¸Á µîÀ» ÇÔ²² ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,645
¹ßÇàÀÏ 2009³â 11¿ù
¸®¼­Ä¡»ç France Innovation Scientifique et Transfert (FIST SA)
ÆäÀÌÁö¼ö  
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
»ùÇÃ
»óǰÄÚµå :103311
209°³ÀÇ ÇÁ·ÎÅ×ÀΠŰ³ª¾ÆÁ¦ Ä¡·á¾à °³¹ß Àü·«¿¡ ´ëÇØ °ËÁõÇϰí, ¾àÁ¦È¸»çÀÇ Æ÷Æ®Æú¸®¿À Ç÷¡´×°ú ½ÅÁ¦Ç° °³¹ß °èȹÀÇ µ¿ÇâÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,553
¹ßÇàÀÏ 2009³â 10¿ù
¸®¼­Ä¡»ç BioSeeker Group AB
ÆäÀÌÁö¼ö 1442 pages
»ùÇÃ
»óǰÄÚµå :111898
GPCR(G´Ü¹éÁú °ø¿ª ¼ö¿ëü) Drug Discovery ±â¼úÀÇ µ¿ÇâÀ» °ËÁõÇϰí, »ê¾÷°è ¹× Çмú°èÀÇ Ãֽбâ¼ú°³¹ß µ¿ÇâÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 6,500
¹ßÇàÀÏ 2009³â 09¿ù
¸®¼­Ä¡»ç Technical Insights, Inc.
ÆäÀÌÁö¼ö  
Ion Channel Modulator Pipelines: Targets and Agents in Development
»ùÇÃ
»óǰÄÚµå :99267
ÀÓ»ó½ÇÇèÁßÀÎ À̿ ä³Î ¸ðµâ·¹ÀÌÅÍÀÇ °³¿ä ¹× ÀáÀ缺, À̿ ä³ÎÀÇ ±¸Á¶ ¹× ¼¼Æ÷ ÀÛ¿ëÀÇ °³¿ä, °íÃâ·Â ½ºÅ©¸®´×, »ó¾÷Àû ¼º°øÀ» À§ÇÑ ÇâÈÄ Àü¸Á µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,195
¹ßÇàÀÏ 2009³â 08¿ù
¸®¼­Ä¡»ç Insight Pharma Reports
ÆäÀÌÁö¼ö 154 pages
Molecular Targeted Cancer Therapies Market Forecast
»ùÇÃ
»óǰÄÚµå :99559
¼¼°è ÁÖ¿ä 7°³±¹ÀÇ 2008¡­2018³âÀÇ ºÐÀÚ Ç¥ÀÛ ¾ÏÄ¡·á ½ÃÀå µ¿Çâ°ú ½ÇÀû¿¡ ´ëÇØ Á¤·®ÀûÀ¸·Î ºÐ¼®Çϰí Ãâ½Ã ¾à ¹× °³¹ß Áß¿¡ ÀÖ´Â ¾àÁ¦ÀÇ ±âȸ¿Í À§Çù, ÇâÈÄ 10³â°£ÀÇ ÁÖ¿ä ºê·£µå¸¦ ƯÁ¤ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 15,200
¹ßÇàÀÏ 2009³â 08¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö  
»ùÇÃ
»óǰÄÚµå :95488
Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦ÀÇ °³¿ä¿Í ÇÁ·ÎÆÄÀϸµ, °³¹ß µ¿Çâ, ¿µ±¹ ¹× ¹Ì±¹¿¡¼­ÀÇ »óȯ, °³¹ßÁß ¹× Ãâ½Ã¿Ï·á Á¦Ç°, ÇâÈÄ ½ÃÀå Àü¸Á µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,950
¹ßÇàÀÏ 2009³â 07¿ù
¸®¼­Ä¡»ç Global Industry Analysts, Inc.
ÆäÀÌÁö¼ö Pages: 558
Innovations in Protein Kinase Therapies: Company pipelines, therapeutic applications and market forecasts
»ùÇÃ
»óǰÄÚµå :87079
´Ü¹éÁú Ű³ª¾ÆÁ¦ Ä¡·áÀÇ ±â¼ú Çõ½Å¿¡ °üÇÑ ÃֽŠÁ¤º¸¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,835
¹ßÇàÀÏ 2009³â 05¿ù
¸®¼­Ä¡»ç Business Insights
ÆäÀÌÁö¼ö 287 pages